ReviewHepatology forum2026
MASLD and viral hepatitis overlap: An emerging dual burden in chronic liver disease.
Review in Hepatology forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent intrahepatic cholestasis secondary to multiple etiologies: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) and viral hepatitis has gained greater focus due to the global increase in chronic liver diseases. This convergence of conditions creates a unique clinical entity characterized by complex molecular interactions, difficult diagnosis, and treatment issues. The frequency of MASLD alongside viral hepatitis is becoming more prevalent. Overlapping pathogenic mechanisms, such as insulin resistance, activation of pro-inflammatory cytokines, hepatic steatosis, and persistent viral infection, establish a synergistic pathophysiological relationship that exacerbates fibrosis and liver damage. Non-invasive fibrosis assessments, multimodal imaging, and, in certain cases, liver biopsies are often required to achieve diagnostic accuracy. This review intends to examine the epidemiological overlap, shared pathophysiological mechanisms, diagnostic hurdles, and management challenges associated with the concurrent manifestation of MASLD and viral hepatitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.